Sound Bites With Melissa Joy Dobbins

According to the Centers for Disease Control and Prevention, more than 40% of American adults have obesity, costing the U.S. healthcare system an estimated $173 billion annually. The development of incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), marks a major advance in obesity treatment. Registered Dietitian Nutritionists (RDNs) play a crucial role in providing medical nutrition therapy (MNT) to people using these medications as part of comprehensive obesity care. Tune into this episode to learn about: ●       the new paper published in JAND about injectable weight loss medications and lifestyle interventions ●       the unique and evolving role of RDNs in obesity care ●       why this new class of obesity medications has become so popular ●       how these medications work ●       the amount of weight loss needed to reduce obesity related comorbidities ●       the evolution of different terms for these medications ●       the